First Time Loading...

Shandong Lukang Pharmaceutical Co Ltd
SSE:600789

Watchlist Manager
Shandong Lukang Pharmaceutical Co Ltd Logo
Shandong Lukang Pharmaceutical Co Ltd
SSE:600789
Watchlist
Price: 7.79 CNY -1.02% Market Closed
Updated: Jun 1, 2024
Section:
 

Relative Value

The Relative Value of one Shandong Lukang Pharmaceutical Co Ltd stock under the Base Case scenario is 12.67 CNY. Compared to the current market price of 7.79 CNY, Shandong Lukang Pharmaceutical Co Ltd is Undervalued by 38%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
12.67 CNY
Undervaluation 38%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
66
vs Industry
68
Median 3Y
1.1
Median 5Y
1.3
Industry
2.4
More Details
26.1
P/E
P/E
Price to Earnings
26.1
vs History
82
vs Industry
19
Median 3Y
46
Median 5Y
46
Industry
22.4
More Details
11
P/OCF
P/OCF
Price to OCF
11
vs History
82
vs Industry
34
Median 3Y
19
Median 5Y
19.5
Industry
16.9
More Details
14.8
P/FCFE
P/FCFE
Price to FCFE
14.8
vs History
39
vs Industry
26
Median 3Y
23
Median 5Y
-16.4
Industry
22.6
More Details
1.9
P/B
P/B
Price to Book Value
1.9
vs History
38
vs Industry
41
Median 3Y
1.8
Median 5Y
1.9
Industry
2
More Details
1.5
EV/S
EV/S
Enterprise Value to Sales
1.5
vs History
68
vs Industry
62
Median 3Y
1.5
Median 5Y
1.8
Industry
2.5
More Details
6.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.3
vs History
80
vs Industry
34
Median 3Y
6.9
Median 5Y
7.1
Industry
5.1
More Details
25.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
25.4
vs History
87
vs Industry
14
Median 3Y
42.6
Median 5Y
43.6
Industry
13.3
More Details
25.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
25.4
vs History
87
vs Industry
18
Median 3Y
42.6
Median 5Y
43.6
Industry
16.6
More Details
14.6
EV/OCF
EV/OCF
Enterprise Value to OCF
14.6
vs History
82
vs Industry
29
Median 3Y
25.9
Median 5Y
25.3
Industry
15.7
More Details
36.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
36.1
vs History
14
vs Industry
13
Median 3Y
-22
Median 5Y
-18.1
Industry
17.7
More Details
1.3
EV/IC
EV/IC
Enterprise Value to IC
1.3
vs History
50
vs Industry
51
Median 3Y
1.2
Median 5Y
1.3
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Shandong Lukang Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shandong Lukang Pharmaceutical Co Ltd
SSE:600789
7B CNY 1.1 26.1 25.4 25.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
779.7B USD 21.7 127 62.1 70.7
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.9 46.3 34.5 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
353B USD 4.1 9.2 11.3 14.8
US
Merck & Co Inc
NYSE:MRK
318B USD 5.2 137.9 34.4 56.2
UK
AstraZeneca PLC
LSE:AZN
189B GBP 5.1 38 174.7 278.7
CH
Roche Holding AG
SIX:ROG
184.2B CHF 3.1 16 9.1 10.8
CH
Novartis AG
SIX:NOVN
182.3B CHF 3.4 11.5 8.8 12.8
US
Pfizer Inc
NYSE:PFE
162.4B USD 2.9 -525.6 12.7 20.6
P/E Multiple
Earnings Growth
CN
Shandong Lukang Pharmaceutical Co Ltd
SSE:600789
Average P/E: 51.5
26.1
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
127
364%
DK
Novo Nordisk A/S
CSE:NOVO B
46.3
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.2
-21%
US
Merck & Co Inc
NYSE:MRK
137.9
7 598%
UK
AstraZeneca PLC
LSE:AZN
38
175%
CH
Roche Holding AG
SIX:ROG
16
28%
CH
Novartis AG
SIX:NOVN
11.5
17%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -525.6
683%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 142,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.